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Molecular clones of infectious bronchitis virus (IBV), derived from the Vero cell adapted Beaudette strain, were constructed, using an in
vitro assembly method. In vitro transcribed RNA from a cDNA template that had been constructed from seven cDNA fragments,
encompassing the entire genome of IBV, was electroporated into BHK-21 cells. The cells were overlaid onto the susceptible Vero cells and
viable virus was recovered from the molecular clone. The molecularly cloned IBV (MIBV) demonstrated growth kinetics, and plaque size
and morphology that resembled the parental Beaudette strain IBV. The recombinant virus was further manipulated to express enhanced green
fluorescent protein (EGFP) by replacing an open reading frame (ORF) of the group-specific gene, ORF 5a, with the EGFP ORF. The rescued
recombinant virus, expressing EGFP (GIBV), replicated to lower viral titers and formed smaller plaques compared to the parental virus and
the MIBV. After six passages of GIBV, a minority of plaques were observed that had reverted to the larger plaque size and virus from these
plaques no longer expressed EGFP. Direct sequencing of RT-PCR products derived from cells infected with the plaque-purified virus, which
had lost expression of EGFP, confirmed loss of the EGFP ORF. The loss of EGFP expression (D5a IBV) was also accompanied by reversion
to growth kinetics resembling the standard virus and intact recombinant virus. This study demonstrates that the 5a ORF is not essential for
viral multiplication in Vero cells.
D 2004 Elsevier Inc. All rights reserved.
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Infectious bronchitis virus (IBV), a coronavirus, contin-
ues to be one of the most economically important pathogens
in the poultry industry. Coronaviruses are enveloped viruses
with positive sense, 5Vcapped and 3Vpolyadenylated RNA
genomes, that range from 27.6 to 32 kb (Lai and Cavanagh,
1997). Two thirds of the coronavirus genome encodes the
replicase activity, including a viral RNA-dependent RNA
polymerase (RdRp), helicase, and viral proteinases. The
remaining one third of the genome encodes the structural
proteins and small group-specific ORFs (Lai and Cavanagh,
1997).0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.10.045
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E-mail address: ecollisson@cvm.tamu.edu (E.W. Collisson).IBV has four essential structural proteins, the three
membrane proteins, the spike (S), integral membrane (M),
and small envelope (E) proteins, and a phosphorylated,
nucleocapsid (N) protein. The S protein interacts with
cellular receptors and induces cell and viral membrane
fusion (Bosch et al., 2003). N proteins, which interact with
viral genomic RNA, forming ribonucleocapsid (RNP)
complexes, have been associated with replication and
transcription (Baric et al., 1988; Compton et al., 1987;
Robbins et al., 1986). The E and M proteins are localized in
ER-Golgi intermediate compartment and play critical roles
in viral budding (de Haan et al., 1998; Fischer et al., 1998).
Coronaviruses are classified into three distinct groups
by antigenic cross-reactivity and nucleotide sequence
analysis (Fields, 1996). The group I coronaviruses include
human coronavirus 229E, transmissible gastroenteritis
virus (TGEV), feline coronavirus, and feline infectious05) 206–215
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coronavirus OC43, murine hepatitis virus (MHV), and
bovine coronavirus. IBV belongs to the group III coronavi-
ruses, all of which are avian specific. Severe acute respiratory
syndrome coronavirus (SARS CoV) respiratory disease in
humans that resembles IBV in poultry may be distantly
related to group II coronaviruses (Snijder et al., 2003;
Stavrinides and Guttman, 2004). Coronavirus genomes also
encode group-specific ORF that have been reported to
express in infected cells (Lai and Cavanagh, 1997; Liu and
Inglis, 1992; Liu et al., 1991). Functions of these genes are
not well understood, however, deletion of combinations of
several group-specific genes in MHV resulted in in vivo
attenuation (de Haan et al., 2002). Although the functions of
the four IBV group-specific ORF, 3a, 3b, 5a, and 5b are not
known, a Vero cell passaged IBV mutant with a truncated 3b
was viable in vitro and in vivo (Shen et al., 2003).
Reverse genetic systems for human coronavirus 229E,
TGEV, MHV, SARS CoV, and IBV have been developed
using three distinct methodologies. Bacterial artificial
chromosomes (BAC) and vaccinia virus vectors, both of
which can accommodate the large coronavirus genomes,
have been utilized to carry a full-length cDNA clone of the
genome (Almazan et al., 2000; Casais et al., 2001; Gonzalez
et al., 2002; Thiel et al., 2001). A third system relied on the
in vitro assembly of a modest number of cloned cDNAs.
Instead of cloning the entire genome of TGEV into vectors,
Yount et al. (2000) amplified the viral genome into several
fragments by RT-PCR and the cloned amplicons were
ligated through unique restriction sites for in vitro assembly
of the entire genome. This strategy was further modified to
construct an infectious cDNA clone of MHV with their bno
see’mQ technology, in which restriction endonuclease
sequences were incorporated into amplicons, such that upon
enzyme treatment, the endonuclease sites were eliminated
prior to in vitro ligation. The assembled cDNA product was
used as template for in vitro transcription to generate
genomic RNA (Yount et al., 2002). More recently, this
strategy was used to construct a reverse genetic system for
the SARS CoV (Yount et al., 2003).
In the current study, molecular clones of IBV were
generated using the in vitro assembly of cDNA fragments
as a template for transcription of full-length genomic RNA.
We further have demonstrated that the 5a ORF can be
eliminated or replaced by the EGFP ORF while maintain-
ing virus viability. Therefore, this gene is not essential for
viral replication and its ORF may potentially be used as a
site for heterologous gene delivery.
Results
cDNA was constructed that encompassed the entire IBV
genome
The cloning strategy for a full-length IBV-Beaudette
construct is illustrated in Fig. 1A. Five RT-PCR fragmentswere produced that cumulatively amplified the entire
genome of the Vero cell adapted Beaudette IBV strain.
Amplicons, overlapping by about 10 nucleotides, were
designated A through E and the fragment lengths were as
follows; A, 2269 nts; B, 6356 nts; C, 6895 nts; D, 5030
nts; and E, 7058 nts (Fig. 1B). However, consistent with
the report that these regions were toxic or unstable in
bacteria, difficulties arose in cloning the B and C
fragments into bacterial plasmid based cloning vectors
(Casais et al., 2001). Therefore, the B and C fragments
were each cloned as two smaller fragments B1 and B2,
and C1 and C2. Fragments A through C2 were cloned
into the pSMART vector and fragments D through E2
were cloned into pCR-XL-TOPO cloning vectors. In order
to determine the consensus sequence of the genome, two
to five independent clones of each amplicon were
sequenced using a panel of internal primers. Clones with
consensus sequences were used for in vitro assembly of
full-length cDNA template. There were several sequence
differences, distributed throughout the entire genome of
IBV, between our standard cell adapted IBV strain and the
published Beaudette sequence (Table 1). The standard
parental strain of IBV Beaudette used for these studies
had a five nucleotide insertion at position 25,414 between
the M and 5a ORFs, resulting in a genome size of 27,613,
instead of 27,608 nt. The sequence differences were
confirmed by sequencing three independent clones and
direct sequencing of RT-PCR products. A nucleotide
insertion was found in an intergenic sequence of our
strain compared to the original published sequence. In
addition, an E amplicon with a single unique nucleotide
change of A to G at position 25,793 nt, resulting in amino
acid change from Q to R, was used as a marker for the
molecular clone. Full-length cDNA was in vitro assembled
with amplicons conforming with our established consensus
sequence. To increase full-length in vitro ligation effi-
ciency, ordered ligation reactions were used. The appro-
priately sized ligation reaction products were purified from
1% agarose gels before further ligating with neighboring
inserts (Fig. 1C).
IBV generated by in vitro assembly of cDNAs was
indistinguishable from the wild type virus
A full-length genomic transcript of IBV was produced in
vitro using T7 RNA polymerase with the T7 RNA promoter,
incorporated at the 5Vend of fragment A. The final transcript
product was verified by Northern blot analysis using a probe
against 3VUTR (data not shown). Any transcript of a size
comparable to viral genomic RNAwith a detectable 3VUTR
presumably contained the entire genome of IBV because
only the A fragment had a T7 RNA promoter and thus could
initiate transcription.
The transcripts from the full-length cDNA (along with
the N transcript alone), total cellular RNA from IBV
infected Vero cells (positive control), and PBS (negative
Fig. 1. SapI and BsmBI restriction enzyme sites were used for in vitro assembly of the cDNA for the full-length IBV genome. (A) The 5Vend of the A fragment
was amplified with primers that incorporated the T7 RNA polymerase promoter and similarly, a 19 nucleotide polyadenylated tail was inserted at the 3Vend
of E. Gray boxes represent ORF of the IBV genome. Open boxes represent genome fragments amplified by RT-PCR and black boxes represent 5Vand 3V
untranslated regions. (B) DNA amplicons used for in vitro ligation. Each amplicon was digested with the appropriate restriction enzyme and separated from the
plasmid vectors using agarose gel electrophoresis. Lane M represents the 1 kb DNA ladder; lane 1, fragment A prepared by XhoI digestion, CIP treatment and
then SapI restriction enzyme digestion; lane 2, fragment B1 prepared by BsmBI and SapI; lane 3, fragment B2 prepared by digestion with BsmBI and SapI
restriction enzyme; lane 4, fragment C1 prepared by BsmBI and SapI digestion; lane 5, fragment C2 prepared by BsmBI digestion; lane 6, fragment D prepared
by BsmBI digestion; lane 7, fragment E1 prepared by EcoRI digestion followed by BsmBI digestion, and lane 8, the E2 fragment. (C) In vitro orderly ligation
of the generated cDNA fragments. The inserts were ligated stepwise as follows. Lane M represents the 1-kb DNA extension ladder; lane 1, ligation products of
A and B1; lane 2, ligation products of B2 and C1; lane 3, purified ligation product of C2 and D; lane 4, purified ligation product of E1 and E2; lane 5, ligation
products of lanes 1 and 2; lane 6, ligation products of lanes 3 and 4; lane 7, the final ligation product of lane 5 and 6 (shown by the arrow to the right).
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cells, which were then cultured with Vero cells. Three days
after transfection, typical cytopathic effects (CPE), includ-
ing syncytia formation, were seen in cells transfected with
the positive control. Supernatant from the cells, which were
overgrown by 3 days after transfection, were harvested and
passaged into fresh Vero cells. One day after passage, the
positive control showed CPE. Two days after passage, cells
transfected with the transcript of the full-length ligated
cDNAs showed CPE. CPE was never observed in the
negative control cells. We were unable to rescue virus from
full-length IBV RNA transcript without co-transfection of N
transcript, confirming the possible essential role of N
transcript as described by previous reports (Casais et al.,
2001; Yount et al., 2000, 2002). The virus generated by the
molecular cDNA clone was referred to as MIBV. The
derivation of MIBV from the ligated cDNA was confirmed
by RT-PCR sequence identification of the marker mutation
of a G at nt 25,793.
MIBV was further characterized after three rounds of
plaque purification. MIBV formed plaques which wereindistinguishable in size and morphology from standard
Beaudette cell adapted viral plaques (Figs. 2A and B). The
growth kinetics of MIBV and the standard virus were also
compared and found to be similar (Fig. 3).
The 5a gene is not essential for IBV replication in Vero cells
The reverse genetic strategy we adapted for IBV was
used to evaluate whether a small group-specific gene was
necessary for the survival of IBV in cell culture. Fur-
thermore, the replacement with a foreign ORF would be a
first step in developing constructs of IBV as expression
vectors. Because it has been shown that the expression
level of coronavirus genes can be modified by their
transcription regulatory sequences (TRS), rather than add
an additional TRS, a reporter gene was used to replace
most of the 5a ORF, thus maintaining the 5a TRS
sequence. Based on results with MHV, we hypothesized
that IBV group-specific genes would not be necessary for
viral replication in cell culture. The 5a ORF was used
rather than the 3a, 3b region which contains an internal
Table 1
Differences between the Vero cell-adapted IBV strain used in this study and the previously published IBV Beaudette strain
Locationa Nucleotide
differenceb
Amino acid
differencec
Location Nucleotide
difference
Amino acid
difference
Location Nucleotide
difference
Amino acid
difference
32 C-T – 9372 A-G – 22,492 A-G –
222 C-T – 10,754 T-C V-A 22,535 T-C F-L
282 G-A – 10,781 T-C I-T 22,590 C-T –
490 T-C – 11,780 T-A V-D 23,402 G-T S-I
841 C-T S-P 12,136 A-G S-G 23,724 T-A –
1374 G-A – 13,106 C-T – 24,338 T-C –
1845 T-C – 13,178 A-C Q-H 24,508 C-T P-S
2000 C-T A-V 13,646 A-G – 24,661 A-G I-V
2015 A-G C-G 15,302 A-G – 24,716 C-T T-I
2439 A-T G-E 15,594 C-A – 25,342 G-T –
2651 C-T T-M 16,286 C-T – 25,426 G-A –
3169 A-T – 16,718 A-G – 25,458 T-C –
3210 A-G – 17,546 T-C – 25,465 C-T –
3283 A-G K-E 18,195 T-C Y-H 25,793 A-G Q-R
3322 C-A L-I 20,731 T-A L-I 25,901 A-G –
3428 C-A A-D 20,755 C-T L-F 25,904 A-G –
3926 T-C L-S 21,149 A-C N-T 25,928 T-C –
4481 C-A T-N 21,357 A-T K-N 26,054 C-T –
4791 A-G – 21,457 A-G – 26,208 G-T D-Y
5456 T-C L-H 21,459 A-T – 26,403 G-T A-S
5785 C-T L-F 21,628 A-C N-H 26,501 G-T Q-H
5828 C-T P-L 21,711 G-A – 27,048 T-G Y-D
6231 G-A – 22,347 T-C – 27,051 G-T D-Y
7293 A-C – 22,433 A-G K-R 27,069 A-G N-D
7755 A-G – 22,415 A-C N-T 27,466 A-C –
9372 A-G – 22,441 C-G L-V
a According to our Vero-adapted IBV derived sequence. The entire sequence has been submitted to Genbank.
b Left nucleotide according to the previously published sequences and the right nucleotide from our Vero cell-adapted derived strain.
c Left amino acid from the previously published sequences and the right amino acid from our Vero cell-adapted derived strain. – indicates that there was no
amino acid difference.
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essential structural, E protein (Le et al., 1994). The EGFP
ORF was used to replace the 5a ORF, beginning at the
start codon, while the 3Vend of 5a ORF, that included the
stop codon, was kept intact because this region overlaps
with the 5b ORF.
PCR mutagenesis and the bno see’mQ methodology were
used to replace ORF5a with EGFP. The cloning strategy
used to replace most of the 5a ORF with EGFP (D5a/EGFP)Fig. 2. MIBV generated similar sized plaques as the wild type IBV. Vero
cells were infected with each virus and then overlaid with media containing
0.8% agarose. Three days after infection, agarose was removed and cells
were stained with crystal violet. The MIBV plaques are shown in panel A
and standard cell adapted Beaudette IBV, in panel B.is illustrated in Fig. 4A. Three regions, including the EGFP
ORF (Fig. 4B, lane 1), and sequences between a region
upstream of 5a, including ORF M (Fig. 4B, lane 2), a region
downstream of 5a through the 3VUTR (Fig. 4B, lane 3),
were PCR amplified using primers that incorporated the
BsmBI restriction enzyme recognition sequence (Table 2).
These three PCR products were cloned into the pSTBlue
cloning vector and the inserts were excised from the vectors
with the BsmBI restriction enzyme.
The E amplicon was replaced with the D5a/EGFP
amplicon and the full-length infectious cDNA template
was assembled and transcribed as described previously.
Three days after electroporation into BHK cells and co-
culturing with Vero cells, CPE was observed in the positive
control and in the cells transfected with the GIBV RNA
transcript (Fig. 5A). The cells that showed CPE by GIBV
infection also expressed EGFP which was easily detected
under a UV microscope (Fig. 5B). Interestingly, some cells
expressed EGFP before even showing virus infection
induced morphological changes. Following nucleotide
sequencing analysis, it was confirmed that no unintentional
mutations were incorporated into the amplicons used to
construct the recombinant GIBV. Therefore, not only is 5a
expression not essential for viral replication but also it is
possible to replace the 5a with a functional foreign ORF.
Fig. 3. Comparison of the replication kinetics of standard cell-adapted and
recombinant IBV. Standard IBV and recombinant IBV, MIBV, GIBV, and
D5a IBV were used to infect Vero cells and triplicate samples of the
infected cells were harvested every 4 h for 24 h. Total virus was harvested
by freezing and thawing cells three times and the viral titer was measured
by counting plaque forming units/ml at each time point.
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and the standard cell adapted Beaudette IBV differed
To confirm the stability of the recombinant GIBV, the
virus was subsequently passaged in Vero cells. EGFP
expression was detected in each of seven sequential
passages. GIBV was further characterized by comparingFig. 4. Construction of EGFP/D5a amplicon. (A) The 5a ORF was replaced with t
represent PCR products. Arrows indicate the restriction enzyme sites inserted into
M represents the 1-kb DNA molecular size marker; lane 1, PCR product of EGFP
ORF 5a, denoted as G in (A); lane 3; PCR product encompassing 3Vend of 5a OR
(C) Underlined are IBV sequences and bold are EGFP sequences.plaque morphology and one step growth curves. Com-
pared to our standard virus and the virus from the cloned
MIBV, GIBV-generated plaques were much smaller in size
(Fig. 6A). The growth of GIBV was similar to the standard
IBV with maximum growth at 14 h post-infection.
However, GIBV grew to a 10-fold lower titer compared
with the standard Beaudette IBV or MIBV (Fig. 3).
Beyond passage five in Vero cells, the plaque assays of
the GIBV stocks began to demonstrate plaques similar in size
to those formed by our standard virus. Viruses derived from
these plaques had lost the ability to express EGFP. To explain
the phenomena, the region of EGFP insertion/5a replacement
from several plaque purified viruses was RT-PCR amplified
and compared with RT-PCR products of MIBV and the
GIBV expressing EGFP (forming smaller plaques). The RT-
PCR product of the latter was smaller than the GIBV and
MIBV (Fig. 7A). In addition, the region across the insertion
site of EGFP ORF for ten GIBV derived strains that had lost
EGFP expression was amplified by RT-PCR. Sequencing of
the RT-PCR products confirmed that these stains had either
partially or completely lost the EGFP ORF. The 10 strains
examined could be categorized into four distinct groups,
depending on the deletion pattern of the EGFP ORF (Fig.
7B). The 5b ORF of all was maintained and completely
intact while the start codon at the insertion site of the EGFP
was deleted in all of these phenotypic revertants. Interest-
ingly, the size of plaques with the 5a deletions, including a
revertant that had completely lost the EGFP ORF, was
comparable to plaques generated by our standard Beaudette
cell-adapted Beaudette virus (Fig. 6B). When compared with
the standard virus, growth kinetics and maximum titer of thehe EGFP ORF. Open boxes represent ORF of the IBV genome. Black lines
the PCR products. (B) PCR products containing EGFP in place of ORF 5a.
, denoted as F in (A); lane 2, PCR product of M ORF and junction of 5Vof
F and downstream of the ORF through 3VUTR of IBV, denoted as H in (A).
Fig. 5. Expression of EGFP in Vero cells infected with GIBV. (A) GIBV infection produced syncytia typical of the CPE from Vero cells infected with the
standard IBV. (B) Expression of EGFP was observed by UV microscopy. Expression of EGFP could be observed prior to the typical IBV-induced CPE.
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cell adapted Beaudette virus (Fig. 3).Discussion
Molecular clones of several coronaviruses have been
constructed using three different methodologies, vaccinia
virus vectors and BAC as cloning systems, and the in vitro
assembly strategy. In this study, we constructed an
infectious cDNA clone of IBV and recombinant IBV
expressing EGFP instead of 5a protein, using in vitro
assembly which is less labor intensive and allows for easy
manipulation, such as the introduction of targeted mutations.
We chose to use highly attenuated strain of IBV, the Vero
cell-adapted Beaudette US strain as the cDNA backbone
because we hope to eventually use IBV as a gene transfer
vector, as well as to elucidate mechanisms of pathogenesis
and generate new appropriate vaccines. Contrary to the
difficulties stated in a previous report (Casais et al., 2001),
our study has demonstrated that the in vitro assembly
method used to generate infectious RNA from in vitro
assembled cloned cDNAs of TGEV, MHV, and SARS
coronavirus also can be applied to IBV.
This is also the first report that the group III coronavirus
group-specific 5a gene is not essential for viral replication.Fig. 6. EGFP deletion revertant of GIBV showed comparable plaques to
standard IBV or MIBV. After six serial passages of GIBV, heterogeneous-
sized plaques were observed. The arrow indicates typical GIBV plaques
with the smaller size compared to MIBV and the arrow head indicates a
larger plaque from the GIBV stock that was comparable to the standard cell
adapted IBV, and plaques purified from the larger plaques in A are shown in
panel B.Based on studies with MHVand TGEV, in which deletion of
multiple group-specific genes resulted in attenuation of
virulence, group-specific genes of IBV are reasonable
candidates for viral attenuation and foreign gene replace-
ment (de Haan et al., 2002; Sola et al., 2003). However, it
has been shown that these small ORF, including 5a, are
conserved among the various strains of IBV (Brooks et al.,
2004). Therefore, it is likely that 5a is important, if not
critical, for in vivo replication. Further studies will
determine the in vivo role of 5a in pathogenesis and
whether its deletion results in attenuation.
GIBV produced smaller sized plaques compared to our
standard parental virus. Although many recombinant
viruses have been constructed to express EGFP or GFP
without known reports that EGFP is toxic to virus
replication, EGFP was shown in at least one study to
induce cellular apoptosis (Liu et al., 1999). In the current
study, it is possible that infected cells died by apoptosis
because of high expression of EGFP prior to producing
maximum amounts of virus viral replication. This is
consistent with the finding that we could detect expression
of EGFP before cells showed CPE. Alternatively, manip-
ulation of ORF 5a could affect ORF 5b expression. It has
been assumed that gene 5b is expressed by leaky scanning
mechanism (Liu and Inglis, 1992). The EGFP ORF
contained an appropriate Kozak sequence and may have
reduced the expression of 5b. Therefore, reduction in 5b
expression could potentially have been associated with the
observed change in viral replication.
GIBV phenotypic revertants, which lost the EGFP ORF,
maintained an intact 5b ORF, and regained standard
Beaudette cell adapted virus plaque size, growth kinetics
and titer. Based on sequence analysis, four distinct deletion
events were indicated. It has been shown that the GFP
gene has homology with the MHV TRS and hinders
expression of GFP because of abortive transcription
(Fischer et al., 1997). However, we do not favor this
explanation because, contrary to Fisher et al., we had
sufficient expression of EGFP, with recombinant virus
during the first several passages, to be easily detectable
and no sequence similarity could be identified in or around
the deleted region between the IBV TRS and the EGFP
gene. Non-homologous recombination events during IBV
Fig. 7. GIBV phenotypic revertant had lost the EGFP ORF. The absence of the EGFP ORF was confirmed by RT-PCR and nucleotide sequencing of the region
corresponding to nucleotides 25,162 to 25,613 of the standard cell adapted IBV. Compared to GIBV, the GIBV revertant produced a smaller RT-PCR product,
smaller than the E amplicon, suggesting that the revertant had lost the EGFP and 5a ORFs. (A) RT-PCR and PCR products of the region corresponding to
nucleotides 25,162 to 25,613 of GIBV, the phenotypic 5aGFP deletion revertant and the control, E amplicon. The M lanes represent the DNA molecular size
marker; lane 1, RT-PCR product of GIBVexpressing EGFP; lane 2, the RT-PCR product of the phenotypic revertant that had lost expression of EGFP, and 3, as a
control, the PCR product from the E fragment. (B) Alignment of the nucleotide sequences of the region spanning the 5a/EGFP ORF of D5aGFP viruses identified
four distinct types of EGFP deletions. Italicized nucleotides and the positions starred below the sequence alignment represent conserved sequences. Every mutant
lost the EGFP start codon but maintained the 5b start codon (underlined).
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as EGFP, that is not necessary for the viral replication. It is
not clear whether the foreign gene itself or its specific
location in the viral genome causes this spontaneous
deletion event. Furthermore, we cannot conclude whether
deletion of the EGFP gene, under the control of the 5a
TRS, is a general phenomenon of recombinant IBV or a
result of EGFP toxicity.
Coronaviruses have several attractive traits as gene
delivery systems, including their unusually high packaging
capacity, exclusive replication in cytoplasm, excluding any
chance of viral genome incorporation into host chromo-
somes, and the ability to express multiple genes which has
been shown by Thiel et al. (2003). The stability of a
foreign ORF replacing the 5a ORF should be further
examined with genes that encode non-toxic proteins, in
order to determine the replication status and pathogenesis
of these recombinant viruses in vivo. Furthermore, thismethodology provides with a convenient reverse genetic
tool for correlating the pathogenesis with the group-specific
genes of IBV.Materials and methods
Cultured cells and virus
A Vero cell-adapted strain of IBV Beaudette US, from
American Type Culture Collection (Manassas, VA) was
plaque purified three times before use. The virus was
propagated in an African green monkey kidney Vero cell
line, obtained from ViroMed Laboratory (Minnetonka, MN)
and maintained in Dulbecco’s modified eagle medium
(DMEM) containing 5% fetal bovine serum (FBS) supple-
mented with penicillin G (100 units/ml) and streptomycin
(100 Ag/ml). The baby hamster kidney cell line, BHK-21, was
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containing 10% FBS supplemented with antibiotics as
described for Vero cells.
RT-PCR cloning and sequencing of the IBV-Beaudette
genome
Total cellular RNA was extracted from IBV-Beaudette
infected Vero cells with Trizol reagent (Invitrogen,
Carlsbad, CA), according to the manufacturer’s directions.
Reverse transcription was performed with Superscript II
(Invitrogen) and reverse direction primers P1R, P2R,
P3R, BEAUSSR, and GNRT (Table 2), containing BsmBI
and SapI restriction endonuclease recognition sequences.
The IBV sequence, as reported in GenBank (accession
number M95169), was used for primer design and nucleo-
tide sequencing. Each DNA fragment was amplified from
cDNA templates by PCR using Expand Long polymerase
(Boehringer Mannheim Biochemical). In order to transcribe
RNA using T7 RNA polymerase, the T7 RNA promoter
sequence was incorporated into the T7P1F primer. PCR
primer pairs used to amplify genomic regions are listed in
Table 2. PCR amplification of cDNA fragments was
performed using the following conditions; denaturation at
94 8C for 2 min, 10 cycles at 94 8C for 30 s, 55 8C for 30 s,
and 68 8C for 2–6 min depending on the size of the fragment
and 18 cycles of 94 8C for 30 s, 55 8C for 30 s, and 68 8C for
2–6 min (with an additional 20 s for each subsequent cycle).
The PCR products were isolated from agarose gels and
cloned into pCR-XL-TOPO (Invitrogen) or pSMART (Luci-
gen, Middleton, WI) vectors, according to the manufacturer’s
directions.Table 2
Primer pairs used for cloning and mutagenesis of the IBV and GIBV amplicons
Designation Amplicona Polarity Genome locationb
T7P1F A + 1–22
P1R A  2254–2276
P1F B-1 + 2254–2276
NHER B-1  5731–5752
NHEF B-2 + 5748–5771
P2R B-2  8611–8635
P2F C-1 + 8611–8635
SACR C-1  11,926–11,949
SACF C-2 + 11,944–11,972
P3R C-2  15,508–15,531
P3F D + 15,508–15,531
BEAUSSR D  20,543–20,566
BEAUSSF E + 20,543–20,566
GNRT E/H  27,593–27,613
EGFPSF F +
EGFPER F 
BMF G + 24,509–24,535
5ASR G  25,574–25,592
5AEF H + 25,658–25,678
a As described in Fig. 1.
b As derived from the sequence of our Vero cell-adapted, laboratory Beaudette s
c The T7 RNA polymerase recognition sequences shown in bold. Underlined areTwo to four independent clones of each amplicon were
isolated and sequenced by using specific primers and the
ABI dye termination sequencing method. A consensus
sequence was determined by comparison of direct PCR
product sequencing from each independent clone and
amplicons, encoding the consensus sequence of each region
of IBV, were cloned using standard recombinant DNA
techniques (Sambrook et al., 1989).
The entire IBV N ORF, including the 3V UTR, was
amplified by RT-PCR from total cellular RNA extracted
from IBV infected Vero cells, and the RT-PCR product was
cloned into a transcription vector, pGEM-3Zf(+) (Promega,
Madison, WI).
Construction of the D5a/EGFP amplicon
The EGFP ORF (F fragment) was PCR amplified from
pLEGFP-N1 (Clontech Laboratories, Inc., Palo Alto, CA),
using the GFPSF and GFPER primer pair, and cloned into
pSTBlue (Table 2). The region upstream of the 5a ORF (G
fragment) was PCR amplified using the E amplicon as a
template with the 5ASR and BMF primer pair and the
product cloned into pSTBlue (Novagen, Darmstadt, Ger-
many), referred to as 5aS. The region downstream of the 5a
ORF (fragment H which included the 3VUTR and poly-
adenylated tail) was PCR amplified using the E amplicon
and the 5AEF and GNRT primer pair before cloning into the
pCR-XL-TOPO vector (referred to as 5aE). The G fragment
was prepared by digesting 5aS with XhoI and BsmBI
restriction enzymes. The F fragment was digested from the
vector with BsmBI. The G and F fragments were ligated into
the 5aE amplicon which was digested with XhoI and BsmBINucleotide sequencec
5V-TAATACGACTCACTATAGGACTTAAGATAGATATTAATATA-3V
5V-CCTTTCCAGAAGAGCAAATCTCC-3V
5V-GGAGATTTGCTCTTCTGGAAAGG-3
5V-CGTCTCGCGACAACACTCTTAACACTAGC-3V
5V-CGTCTCTGTCGCTAGCTATAAGACCGTGTT-3V
5V-CAAAAGTGCTCTTCGCAGCAAGATC-3V
5V-GATCTTGCTGCGAAGAGCACTTTTG-3V
5V-CGTCTCGGGATCTACTGCAAATGAACATAG-3V
5V-CGTCTCGATCCCCGCGGACACATATTGTAAATATG-3V
5V-CAAAACGTCTCAATGAATCACTAC-3V
5V-GTAGTGATTCATTGAGACGTTTTG-3V
5V-CGTCTCCAACATCTCTTACCAGTAACTTAC-3V
5V-CGTCTCATGTTGGTAACACCTCTTTTACTAG-3V
5V-TTTTTTTTTTTTTTTTTTTGCTCTAACTCTATACTAGCC-3V
5V-CGTCTCATGGTGAGCAAGGGCGAGGAG-3V
5V-CGTCTCCGCTTACTTGTACAGCTCGTCC-3V
5V-ATGGCGGAAAATTGCACACTTGATTC-3V
5V-CGTCTCCACCATCGTCCGTATTTGTTAAGT-3V
5V-CGTCTCTAAGCGTATACGCCCACCCA-3V
train.
BsmBI restriction enzyme recognition sequences.
S. Youn et al. / Virology 332 (2005) 206–215214restriction enzymes. Replacement of 5a sequences with
EGFP ORF was confirmed by sequencing of the D5a/EGFP
amplicon.
In vitro assembly of full-length IBV infectious constructs
Each amplicon, having the consensus sequence, was
prepared from an overnight bacterial culture. Plasmid was
isolated and digested with the indicated restriction endonu-
cleases according to the manufacturer’s directions. Briefly,
the IBV A amplicon was digested with XhoI and treated
with calf intestine alkaline phosphatase (CIP), before
digesting with the SapI enzyme. The IBV E amplicon was
digested with EcoRI, CIP treated and digested with BsmBI.
The B1, B2 and C1 amplicons were digested with BsmBI at
55 8C and then digested with SapI at 37 8C. The C2 and D
amplicons were digested with BsmBI. Inserts of each
amplicon were resolved by electrophoresis on 1% agarose
gels containing crystal violet and isolated with QIAquick
gel extraction kit (QIAGEN Inc., Valencia, CA) according
to the manufacturer’s directions. One picomole of each
cDNA insert was ligated in an ordered reaction (A + B1,
B2 + C1, C2 + D, E1 + E2 or ED5a/EGFP + E2). The
appropriately sized ligation reaction products were purified
from 1% agarose gels and further ligated with neighboring
inserts for 4 h, pooled and ligated overnight (Fig. 1C). The
final ligation product was purified by extracting with a
phenol/chloroform/isoamyl alcohol (25:24:1) mixture and
precipitated with ethanol before using as a template for in
vitro transcription reactions.
In vitro transcription and electroporation
Full-length transcripts of the IBV cDNA constructs were
generated in vitro using the mMESSAGE mMACHINE T7
Ultra kit (Ambion, Austin, TX) according to the manufac-
turer’s direction with certain modifications. The in vitro
transcription reaction was performed at 37 8C for 2 h in 20 Al
reaction mixtures, supplemented with 3 Al of 30 mM GTP,
resulting in a 1:1 ratio of GTP to capping analog. A similar
reaction was performed for the N transcript using a 1:3 ratio
of GTP and capping analog. Before electroporation, the
transcripts were treated with DNase I and analyzed by 1%
denaturing agarose gel (containing 2.2M formaldehyde)
electrophoresis. The identity of the full-length in vitro
transcript was confirmed by northern blot analysis using a
probe against 3VUTR of IBV.
After BHK-21 cells were grown to subconfluence (80%),
treated with trypsin, and washed with cold DEPC treated PBS
twice, they were resuspended in DEPC-treated PBS at a
concentration of 107 cells/ml. RNA transcripts were added to
400 Al of the BHK-21 cell suspension in microfuge tubes on
ice, gently pipetted and transferred to electroporation
cuvettes. Three consecutive electrical pulses of 850 V at 25
AF were given, using the electro-cell manipulator 600, BTX
(Genetronics, Inc., San Diego, CA). The transfected BHK-21cells were diluted 1 to 20 with complete DMEM in 100 mm
cell culture Petri dishes and co-cultured with 2  106 Vero
cells/dish.
One-step growth curve
Triplicate wells of Vero cells in six-well plates were
infected with virus at a multiplicity of infection (m.o.i.) of 2
to 3. The cells were harvested every 4 h for 24 h and stored
at 80 8C until they were used for quantification by
titration. The cells were three times frozen and thawed, and
10-fold serially diluted in DMEM without serum. Two
hundred microliters of each dilution were inoculated into
six-well plates for an hour, washed with PBS and overlaid
with DMEM, containing 2% FBS, 0.8% agarose, before
incubating at 37 8C for 3 days. The plaques were counted
after removing the agarose overlay from the cells and
staining the monolayer with crystal violet.Acknowledgments
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